Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Cash from Financing Activities (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Cash from Financing Activities for 5 consecutive years, with $42.4 million as the latest value for Q4 2020.

  • On a quarterly basis, Cash from Financing Activities changed N/A to $42.4 million in Q4 2020 year-over-year; TTM through Dec 2020 was $66.7 million, a 1272.88% increase, with the full-year FY2024 number at $51.9 million, up 110.08% from a year prior.
  • Cash from Financing Activities was $42.4 million for Q4 2020 at Forte Biosciences, up from $166000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $87.2 million in Q2 2017 to a low of -$1.8 million in Q3 2017.
  • A 5-year average of $12.8 million and a median of $968000.0 in 2019 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 379052.17% in 2017, then tumbled 133.79% in 2018.
  • Forte Biosciences' Cash from Financing Activities stood at -$23000.0 in 2016, then plummeted by 5726.09% to -$1.3 million in 2017, then soared by 2228.21% to $28.5 million in 2018, then crashed by 89.18% to $3.1 million in 2019, then skyrocketed by 1273.72% to $42.4 million in 2020.
  • Per Business Quant, the three most recent readings for FBRX's Cash from Financing Activities are $42.4 million (Q4 2020), $166000.0 (Q3 2020), and $24.1 million (Q2 2020).